Abiraterone and Increased Survival in Metastatic Prostate Cancer
Open accessThe DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index; 17 of the 40 sources its claims cite were checked for support.
Abstract
BACKGROUND: Biosynthesis of extragonadal androgen may contribute to the progression of castration-resistant prostate cancer. We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy. METHODS: We randomly assigned, in a 2:1 ratio, 1195 patients who had previously received docetaxel to receive 5 mg of prednisone twice daily with either 1000 mg of abiraterone acetate (797 patients) or placebo (398 patients). The primary end point was overall survival. The secondary end points included time to prostate-specific antigen (PSA) progression (elevation in the PSA level according to prespecified criteria), progression-free survival according to radiologic findings based on prespecified criteria, and the PSA response rate. RESULTS: After a median follow-up of 12.8 months, overall survival was longer in the abiraterone acetate-prednisone group than in the placebo-prednisone group (14.8 months vs. 10.9 months; hazard ratio, 0.65; 95% confidence interval, 0.54 to 0.77; P<0.001). Data were unblinded at the interim analysis, since these results exceeded the preplanned criteria for study termination. All secondary end points, including time to PSA progression (10.2 vs. 6.6 months; P<0.001), progression-free survival (5.6 months vs. 3.6 months; P<0.001), and PSA response rate (29% vs. 6%, P<0.001), favored the treatment group. Mineralocorticoid-related adverse events, including fluid retention, hypertension, and hypokalemia, were more frequently reported in the abiraterone acetate-prednisone group than in the placebo-prednisone group. CONCLUSIONS: The inhibition of androgen biosynthesis by abiraterone acetate prolonged overall survival among patients with metastatic castration-resistant prostate cancer who previously received chemotherapy. (Funded by Cougar Biotechnology; COU-AA-301 ClinicalTrials.gov number, NCT00638690.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 7 Not checked · 36 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A unique molecular alteration described in castration-resistant prostate cancer is the up-regulation of androgen biosynthesis enzymes, leading to an increase in intratumoral androgen concentrations, which can exceed the levels measured in the blood.”
§ Abiraterone and Increased Survival in Metastatic Prostate Cancer > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [7] matched to “Gene Expression Analysis of Human Prostate Carcinoma during Hormonal Therapy Identifies Androgen-Responsive Genes and Mechanisms of Therapy Resistance” (2004) source
- Partly supportedcites [8] matched to “Increased Expression of Genes Converting Adrenal Androgens to Testosterone in Androgen-Independent Prostate Cancer” (2006) sourceExperimental — accuracy not yet measured
The Abstract and Discussion (page numbers unavailable) report increased expression of androgen-metabolism genes in androgen-independent prostate cancer and propose enhanced intracellular conversion of adrenal androgens as a mechanism for substantial tissue androgen levels. The paper does not state that intratumoral androgen concentrations exceed blood levels; its tissue comparison is with normal or nonneoplastic prostate. (LLM, conf=0.88)
- Partly supportedcites [9] matched to “Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth” (2008) sourceExperimental — accuracy not yet measured
The Results report up-regulated transcripts for androgen-biosynthesis enzymes in castration-resistant metastases and say tumor testosterone concentrations exceeded equivalent concentrations in the patients’ serum. But the Discussion says the processes sustaining intratumoral androgens have yet to be determined and proposes enzyme modulation as a possible mechanism; it does not establish that the up-regulation caused the higher concentrations. No page number is available in our copy. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Treatment with abiraterone acetate did not appear to increase the risk of metabolic changes or symptoms associated with chronic androgen deprivation.”
§ Abiraterone and Increased Survival in Metastatic Prostate Cancer > Discussion
What the sources say
- Could not verifycites [42] matched to “Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy: Observational Study of Veterans With Prostate Cancer” (2010) sourceExperimental — accuracy not yet measured
The Methods passage describes GnRH agonists, orchiectomy, and oral antiandrogens, but does not identify abiraterone acetate as a treatment studied. The Results and Discussion address diabetes and cardiovascular outcomes for those treatments, not metabolic changes or symptoms during abiraterone treatment. Searches for “abiraterone acetate” and the claimed metabolic changes and symptoms found no passage addressing that specific claim. (LLM, conf=0.77)
- Could not verifycites [43] matched to “Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk: A Science Advisory From the American Heart Association, American Cancer Society, and American Urological Association: Endorsed by the American Society for Radiation Oncology” (2010) sourceExperimental — accuracy not yet measured
The 'Adverse Effects of ADT' section describes metabolic changes associated with androgen-deprivation therapy generally, but does not assess abiraterone acetate. Searches for 'abiraterone acetate' and 'symptoms associated with chronic androgen deprivation' found no passage addressing whether abiraterone increases those risks. (LLM, conf=0.76)
- Not checked yetcites [44] matched to “Management of Complications of Prostate Cancer Treatment” (2008) source
- Not checked yetcites [45] matched to “Contribution of Androgen Deprivation Therapy to Elevated Osteoclast Activity in Men with Metastatic Prostate Cancer” (2004) source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“These results show that continued androgen-receptor signaling contributes to disease progression”
§ Abiraterone and Increased Survival in Metastatic Prostate Cancer > Discussion
What the sources say
- Not checked yetcites [2] matched to “Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling Axis” (2005) source
- Supportedcites [10] matched to “Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break?” (2009) source
The Abstract of the Attard et al. (2009) Cancer Cell preview states that 'clinical data from abiraterone acetate and MDV-3100 confirm continued androgen receptor (AR) addiction in a significant proportion of castration-resistant prostate cancers,' and the Main Text adds that 'the growth of the majority of cancer cells in many patients with cancers recurring after castration remains dependent on the AR signaling axis,' with nuclear AR expression persisting in metastases and AR transcriptional activity described as 'required for prostate cancer progression' (Hormone-Driven Oncogenesis). The conclusion reiterates that a significant proportion of CRPC finds AR signaling 'a hard habit to break.' This covers the claim's substance — persistent AR signaling contributing to progression in metastatic CRPC — though the source phrases it as addiction/persistence in a significant proportion rather than in all patients. (LLM, conf=0.88)
- Not checked yetcites [31] matched to “Novel Therapeutic Strategies for Castration Resistant Prostate Cancer: Inhibition of Persistent Androgen Production and Androgen Receptor Mediated Signaling” (2011) source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In phase 1–2 trials, treatment with abiraterone acetate, either as a single agent or in combination with low-dose glucocorticoids such as prednisone, resulted in significant antitumor activity among both patients with progressing castration-resistant prostate cancer who had not received chemotherapy and those who had received chemotherapy.”
§ Abiraterone and Increased Survival in Metastatic Prostate Cancer > Abstract > CONCLUSIONS
What the sources say
- Partly supportedcites [15] matched to “Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer” (2009) sourceExperimental — accuracy not yet measured
The Abstract Patients and Methods (p.1) and Introduction state this phase I/II trial enrolled castrate, chemotherapy-naive CRPC patients only, and the PATIENTS AND METHODS > Patients section explicitly excludes 'Patients who had previously received cytotoxic chemotherapy or a radiopharmaceutical'; the antitumor activity figures (≥50% PSA decline in 67% of 42, RECIST partial responses in 9/24, Abstract Results) therefore apply solely to the chemotherapy-naive population. The low-dose glucocorticoid component is supported in that the study prospectively added dexamethasone 0.5 mg/d at progression and reversed resistance in 33% of patients (Abstract Results; Discussion). What this source does not support is the post-chemotherapy arm of the claim: the Discussion mentions only that a phase III study of abiraterone plus prednisone in docetaxel-treated patients 'is now being evaluated,' with no results reported here. (LLM, conf=0.85)
- Supportedcites [16] matched to “Abiraterone Acetate Is Well Tolerated Without Concomitant Use of Corticosteroids” (2010) source
In the body of this correspondence (section 'Abiraterone Acetate Is Well Tolerated Without Concomitant Use of Corticosteroids'), the authors open by summarising the three multicenter phase I/II studies of abiraterone acetate in CRPC (chemotherapy-naive Ryan et al, and the post-docetaxel Reid et al and Danila et al studies listed in their References) and state that their prechemotherapy data 'confirmed the significant antitumor activity of abiraterone acetate' (radiologic regression, PSA and circulating tumour cell decreases), that the combination with low-dose corticosteroids (dexamethasone/prednisone) gave 'durable secondary tumor responses... in 25% of patients', and close by affirming 'the significant and durable antitumor activity and the satisfactory safety profile of abiraterone acetate at 1,000 mg daily'. Low-dose prednisone is explicitly named. This source is correspondence reporting/summarising those trials rather than a primary trial report, but it states every element attributed to it here. (LLM, conf=0.82)
- Partly supportedcites [17] matched to “Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven” (2008) sourceExperimental — accuracy not yet measured
Our copy is a single phase I trial, and it confirms significant antitumor activity (PSA declines ≥30%/≥50% in 66%/57% of 21 patients, RECIST partial responses in 5 of 8) in chemotherapy-naive CRPC (Antitumor Activity section), with low-dose dexamethasone 0.5 mg/d added at progression reinducing sensitivity in 4 of 15 patients (Reversal of Resistance section). However, the post-chemotherapy arm and the phase II results are not reported here: the Discussion (B2 C1 C2) states only that these findings 'have led to the phase II evaluation... in both chemotherapy-naïve and docetaxel-treated patients... data from this evaluation will be reported soon,' and the Patients section explicitly excluded men previously treated with chemotherapy. Prednisone is not the glucocorticoid used in this paper (dexamethasone was), so the 'phase 1-2 trials... both chemotherapy-naive and post-chemotherapy' scope is not carried by this source. (LLM, conf=0.78)
- Supportedcites [18] matched to “Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer” (2010) source
Our copy covers every element of the summary sentence. The Abstract and Results describe this phase II trial of abiraterone acetate 1,000 mg daily with low-dose prednisone 5 mg twice daily in 58 men with progressive metastatic CRPC after docetaxel failure, reporting significant antitumor activity (confirmed ≥ 50% PSA decline in 36%, partial responses in 4/22 RECIST-evaluable patients, ECOG improvement in 28%). The Introduction states that 'Significant antitumor effects were seen in patients with progressive CRPC who had not received prior chemotherapy' (citing the phase I trial, Attard 2008, and the phase II chemo-naive AA-plus-prednisone study, Ryan 2009) and that 'In a separate trial, we showed significant antitumor effects of abiraterone acetate (AA) monotherapy in this patient group' (post-docetaxel, Reid/Danila), i.e. activity with AA alone as well as with low-dose steroid, in both chemotherapy-naive and post-chemotherapy settings. The Discussion likewise frames this as 'the second trial showing the activity of AA in patients ... who have progressed on chemotherapy.' (LLM, conf=0.85)
- Partly supportedcites [19] matched to “Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate” (2010) sourceExperimental — accuracy not yet measured
Our copy directly supports the trial/patient-population part: the Conclusion (p. 1) and DISCUSSION (p. 5) state that abiraterone acetate 1,000 mg had significant antitumor activity in post-docetaxel CRPC (≥50% PSA declines in 51%, with radiologic, symptomatic and CTC support), and the INTRODUCTION (p. 2) plus DISCUSSION (p. 6) report the authors' own phase I and phase II pre-docetaxel (chemotherapy-naïve) studies as showing abiraterone 'well tolerated and active'. What our copy does not support is the efficacy attribution to a glucocorticoid combination: low-dose glucocorticoids (and eplerenone) appear only as management of mineralocorticoid-excess toxicities (Treatment and Procedures, p. 3; Safety, p. 5; DISCUSSION, p. 6), the trial itself was single-agent abiraterone, and prednisone co-administration is mentioned only as the design of the subsequent phase III trial (DISCUSSION, p. 5), not as a phase 1-2 activity result. (LLM, conf=0.78)
- Partly supportedcites [20] matched to “Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy” (2010) sourceExperimental — accuracy not yet measured
Ryan et al. (2010) supports only part of the sentence: the DISCUSSION (p. 1) states 'Abiraterone acetate has significant activity in patients with CRPC, as evidenced by a PSA response rate of 58% in this phase I trial,' and RESULTS/Efficacy report confirmed ≥50% PSA declines in 55%-58% of men with chemotherapy-naïve progressive CRPC, including 47% of those with prior ketoconazole. However, this is a single-agent phase I dose-escalation trial only — 'Prior chemotherapy for prostate cancer was not allowed' (Major Eligibility Criteria), and the DISCUSSION states the exclusion of prior-chemotherapy patients was intentional, with 'ongoing studies...evaluating abiraterone in patients with both chemotherapy-refractory and chemotherapy-naïve CRPC,' so the post-chemotherapy activity attributed here is not from this paper. Glucocorticoids were also not part of the tested regimen: prednisone/corticosteroids were used reactively to manage mineralocorticoid toxicity, and the authors only 'suggest that a low dose of a corticosteroid, such as prednisone, be administered with abiraterone acetate in future studies'; the DISCUSSION notes 'the impact of concurrent prednisone on response proportion and durability...is not known.' (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The safety profile observed in the group of patients who received abiraterone acetate was similar to that observed in earlier clinical studies.”
§ Abiraterone and Increased Survival in Metastatic Prostate Cancer > Discussion
What the sources say
- Partly supportedcites [15] matched to “Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer” (2009) sourceExperimental — accuracy not yet measured
Our copy details the safety profile of the 1,000-mg abiraterone acetate group in RESULTS > Safety Profile (secondary mineralocorticoid excess: hypokalemia 88%, hypertension 40%, fluid overload 31%, managed with eplerenone; grade 3 transaminase elevation in 2 patients; grade 1 headaches/joint aches) and calls it 'effective, well-tolerated' in the DISCUSSION, so the first half of the claim is grounded. However, no passage states that this profile was 'similar to that observed in earlier clinical studies'; the only cross-study safety remarks compare abiraterone with ketoconazole trials (grade >=3 toxicities in up to 30% of patients, all requiring hydrocortisone) and explicitly caution that 'it is difficult to make any comparisons.' The prior abiraterone phase I experience is referenced (ref 15) as having identified the 1,000-mg dose, not as a matched safety comparison. The comparative/similarity element is therefore unsupported by our copy. (LLM, conf=0.68)
- Partly supportedcites [17] matched to “Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven” (2008) sourceExperimental — accuracy not yet measured
Our copy documents this trial's own safety profile (Safety and Tolerability: dose escalation to 2,000 mg achieved, no treatment-related grade 3 or 4 toxicities, hypertension/hypokalemia/edema controlled with eplerenone; DISCUSSION: toxicities predominantly due to secondary mineralocorticoid excess), and the INTRODUCTION notes that first-in-man studies reported abiraterone acetate was safe when given daily for 12 days to men with prostate cancer. However, no passage compares the two or states the profiles were similar; the only 'similar' statement in the paper is of hypertension incidence across dose levels within this study, and the DISCUSSION frames this as 'the first study to demonstrate that selective and continuous inhibition of CYP17 is safe', with the earlier clinical experience being short-course dosing in noncastrate men. The comparative element of the claim ('similar to that observed in earlier clinical studies') is therefore not supported by this source. (LLM, conf=0.65)
- Partly supportedcites [20] matched to “Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy” (2010) sourceExperimental — accuracy not yet measured
Ryan et al. (2010) describe their own safety findings as acceptable and consistent with expected CYP17 inhibition (DISCUSSION: 'The adverse event and steroid endocrine profiles were consistent with anticipated outcomes of selective CYP17 inhibition'; well tolerated through 1,000 mg/d with no MTD and no toxicity difference by prior ketoconazole exposure, DISCUSSION). However, the only external comparison our copy makes is to a CONCURRENT study, not to earlier clinical studies: RESULTS (Dose Escalation) states 'These findings paralleled a concurrent study with abiraterone acetate.' The claim's framing of similarity to 'earlier clinical studies' is therefore not supported by this source. (LLM, conf=0.68)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
23 more claims · 3 with their cited sources checked
Create a free account to see all 50 claims and to verify the 23 references still open.
- It may state two separate claims as one. 10
- The quote only partly states this claim. 3
- Probably not a substantial claim. 11
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Abiraterone acetate is an orally active prodrug of abiraterone, a potent P450c17 inhibitor (316) indicated for treatment of castration-resistant prostate cancer (317, 318).”
From Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline (2018) · cites this paper as [317]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Although improvements in clinical outcomes have been observed with novel therapies [20–31], their approval has resulted in uncertainties on optimal treatment sequencing, and utilization of these treatments is limited, demonstrating the need for improved real-world treatment practices.”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [20]
In the citing paper
“Abiraterone is a potent CYP17A1 inhibitor that efficiently inhibits testosterone production120 and is used to treat prostate cancer.”
From Management challenges and therapeutic advances in congenital adrenal hyperplasia (2022) · cites this paper as [120]
In the citing paper
“Additionally, androgen biosynthesis from C21 precursors can be reduced by CYP17A1 inhibition with abiraterone as successfully applied for the treatment of CRPC (Attard et al., 2008, de Bono et al., 2011, James et al., 2017).”
From Intracrine androgen biosynthesis, metabolism and action revisited (2018) · cites this paper as de Bono et al., 2011
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647 · cited 2×
“Arthralgia 215 (27) 33 (4) 0 89 (23) 16 (4) 0”
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 2×
“Arthralgia 215 (27) 33 (4) 0 89 (23) 16 (4) 0”
Self-citationSipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572 · cited 3×
“Bone pain 194 (25) 42 (5) 2 (<1) 110 (28) 25 (6) 4 (1)”
de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Miller, W. L., & Auchus, R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0013 · Cited by 2,458
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278
Scher, H. I., Halabi, S., Tannock, I., Morris, M., Sternberg, C. N., Carducci, M. A., Eisenberger, M. A., Higano, C., Bubley, G. J., Dreicer, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4487 · Cited by 2,241 · cited 1×
“Fluid retention and edema 241 (31) 16 (2) 2 (<1) 88 (22) 4 (1) 0”
Self-citationde Bono, J. S., Scher, H. I., Montgomery, R. B., Parker, C., Miller, M. C., Tissing, H., Doyle, G. V., Terstappen, L. W. W. M., Pienta, K. J., & Raghavan, D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0872 · Cited by 2,182 · cited 2×
“Nausea 233 (30) 12 (2) 1 (<1) 124 (32) 10 (3) 0”
Self-citationDevelopment of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases
Daut, R. L., Cleeland, C. S., & Flanery, R. C. (1983) · Pain · doi:10.1016/0304-3959(83)90143-4 · Cited by 1,562
Cited by
Items 801–900 of 1,010
Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer
Norris, J. D., Miner, S. J., Baker, J. G., Stagg, D. B., Wardell, S. E., Park, S. H., Alley, H. M., Baldi, R. M., Yllanes, A. P., Andreano, K. J., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci87328 · Cited by 57
Targeting Galectin-1 Impairs Castration-Resistant Prostate Cancer Progression and Invasion
Shih, T., Liu, R., Wu, C., Li, X., Xiao, W., Deng, X., Kiss, S., Wang, T., Chen, X., Carney, R. P., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0157 · Cited by 60
“either docetaxel, CYP17A1 inhibitor abiraterone, or AR inhibitor enzalutamide is used to treat CRPC after ADT has failed (36-39).”
MethodDisparities in Castration-Resistant Prostate Cancer Trials
Spratt, D. E., & Osborne, J. R. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.1751 · Cited by 59
Okegawa, T., Ninomiya, N., Masuda, K., Nakamura, Y., Tambo, M., & Nutahara, K. (2018) · The Prostate · doi:10.1002/pros.23501 · Cited by 56
Bone Metastases and Health in Prostate Cancer: From Pathophysiology to Clinical Implications
Baldessari, C., Pipitone, S., Molinaro, E., Cerma, K., Fanelli, M., Nasso, C., Oltrecolli, M., Pirola, M., D’Agostino, E., Pugliese, G., et al. (2023) · Cancers · doi:10.3390/cancers15051518 · Cited by 74
Morris, M. J., Heller, G., Hillman, D. W., Bobek, O. J., Ryan, C. J., Antonarakis, E. S., Bryce, A. H., Hahn, O. M., Beltran, H., Armstrong, A. J., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02394 · Cited by 61
“Failure to thrive 14 (8) 15 (10) 29 (9)”
Self-citationAdvances in the treatment of metastatic prostate cancer
Gebrael, G., Fortuna, G. G., Sayegh, N., Swami, U., & Agarwal, N. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.06.009 · Cited by 59
The insulin-like growth factor (IGF) axis as an anticancer target in prostate cancer
Heidegger, I. M., Massoner, P., Sampson, N., & Klocker, H. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.07.026 · Cited by 61
Kruczek, K. R., Ratterman, M., Tolzien, K., SULO, S. S., Lestingi, T. M., & Nabhan, C. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.530 · Cited by 61
“(de Bono et al, 2010; Kantoff et al, 2010; de Bono et al, 2011; Scher et al, 2012).”
BackgroundAndrogen synthesis inhibitors in the treatment of castration-resistant prostate cancer
Stein, M., Patel, N., Bershadskiy, A., Sokoloff, A., & Singer, E. A. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.129133 · Cited by 67
Lorente, D., Omlin, A. G., Ferraldeschi, R., Pezaro, C. J., Pérez-López, R., Mateo, J., Altavilla, A., Zafeirou, Z., Tunariu, N., Parker, C. C., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.531 · Cited by 62
“Both abiraterone, a CYP17A1 inhibitor that suppresses androgen and oestrogen synthesis, and enzalutamide, a potent next-generation antiandrogen, have been shown to improve overall survival in large, randomised, placebo-controlled phase III trials (de Bono et al, 2011; Scher et al, 2012).”
BackgroundTwardowski, P. W., Beumer, J. H., Chen, C. S., Kraft, A. S., Chatta, G. S., Mitsuhashi, M., Ye, W., Christner, S. M., & Lilly, M. B. (2013) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328361feb0 · Cited by 57
Tumor-Associated Antigens for Specific Immunotherapy of Prostate Cancer
Kießling, A., Wehner, R., Fuessel, S., Bachmann, M. P., Wirth, M. P., & Schmitz, M. (2012) · Cancers · doi:10.3390/cancers4010193 · Cited by 59
Kalina, J. L., Neilson, D. S., Comber, A. P., Rauw, J. M., Alexander, A., Vergidis, J., & Lum, J. J. (2017) · Cancers · doi:10.3390/cancers9020013 · Cited by 58
“Indeed, abiraterone plus prednisone extended overall survival, compared to prednisone alone, in two landmark phase III studies involving both chemotherapy-naïve CRPC, as well as men previously treated with docetaxel [21,22].”
BackgroundMorris, M. J., Rumble, R. B., Basch, E., Hotte, S. J., Loblaw, A., Rathkopf, D. E., Celano, P., Bangs, R., & Milowsky, M. I. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.0619 · Cited by 57
Niu, Y., Guo, C., Wen, S., Tian, J., Luo, J., Wang, K., Tian, H., Yeh, S., & Chang, C. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.09.020 · Cited by 60
Circulating tumor DNA alterations in patients with metastatic castration‐resistant prostate cancer
Sonpavde, G., Agarwal, N., Pond, G. R., Nagy, R. J., Nussenzveig, R. H., Hahn, A. W., Sartor, O. A., Gourdin, T. S., Nandagopal, L., Ledet, E. M., et al. (2019) · Cancer · doi:10.1002/cncr.31959 · Cited by 57
Factors Associated With Use of Sipuleucel-T to Treat Patients With Advanced Prostate Cancer
Caram, M. E. V., Ross, R. D., Lin, P., & Mukherjee, B. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.2589 · Cited by 62
Human Steroid Biosynthesis for the Oncologist
Auchus, M. L., & Auchus, R. J. (2012) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e3182408567 · Cited by 56
“Abiraterone acetate, a 17-hydroxylase/17,20-lyase (CYP17A1) and thus androgen biosynthesis inhibitor, has been recently approved for the treatment of castration-resistant prostate cancer (CRPC).(10) Consequently, the evolution of treatment has generally progressed from surgery to receptor antagonists to hormone synthe…”
BackgroundThe promise of circulating tumor cell analysis in cancer management
Mateo, J., Gerlinger, M., Rodrigues, D. N., & Bono, J. S. D. (2014) · Genome biology · doi:10.1186/s13059-014-0448-5 · Cited by 58
“of the CYP-17 inhibitor abiraterone (Zytiga, Janssen Biotech) [35].”
BackgroundLv, S., Song, Q., Chen, G., Cheng, E., Chen, W., Cole, R. N., Wu, Z., Pascal, L. E., Wang, K., Wipf, P., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci141335 · Cited by 60
Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase
Lin, H., Mak, B., Yeung, N. K., Huynh, K., Meikle, T. G., Mellett, N. A., Kwan, E. M., Fettke, H., Tran, B., Davis, I. D., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103625 · Cited by 63
Fallah, J., Xu, J., Weinstock, C., Brave, M. H., Bloomquist, E. W., Fiero, M. H., Schaefer, T., Pathak, A. B., Abukhdeir, A. M., Bhatnagar, V., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.01868 · Cited by 59
Fred Saad, C. (2013) · Therapeutic Advances in Urology · doi:10.1177/1756287213490054 · Cited by 63
Lévesque, É., Huang, S., Audet‐Walsh, É., Lacombe, L., Bao, B., Fradet, Y., Laverdière, I., Rouleau, M., Huang, C., Yu, C., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2812 · Cited by 61
“CYP17A1 is one of the early steps in the biosynthesis of sex steroids and the molecular target of abiraterone that improves survival after docetaxel treatment in patients with CRPC (8).”
BackgroundInfluentialJames, N. D., Pirrie, S. J., Pope, A., Barton, D., Andronis, L., Goranitis, I., Collins, S. I., McLaren, D. B., O’Sullivan, J. M., Parker, C. C., et al. (2016) · Health Technology Assessment · doi:10.3310/hta20530 · Cited by 57
Self-citationTreatments for Metastatic Prostate Cancer (mPC): A Review of Costing Evidence
Norum, J., & Nieder, C. (2017) · PharmacoEconomics · doi:10.1007/s40273-017-0555-8 · Cited by 59
“Studies have indicated a survival gain of about 4 months [13].”
BackgroundTestosterone Levels and Prostate Cancer Prognosis: Systematic Review and Meta-analysis
Claps, M., Petrelli, F., Caffo, O., Amoroso, V., Roca, E., Mosca, A., Maines, F., Barni, S., & Berruti, A. (2018) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2018.01.005 · Cited by 62
Modulation of AKR 1C2 by curcumin decreases testosterone production in prostate cancer
Ide, H., Lu, Y., Noguchi, T., Muto, S., Okada, H., Kawato, S., & Horie, S. (2018) · Cancer Science · doi:10.1111/cas.13517 · Cited by 55
“Currently, abiraterone, an inhibitor of cytochrome CYP17A1, has yielded high durable responses in CRPC patients, by reducing testosterone levels.(25) We studied the effect of curcumin on the proliferation of other cancer cell lines, such as T24 and RT4 bladder cancer cells, by MTS assay.”
BackgroundHSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer
Alyamani, M., Emamekhoo, H., Park, S., Taylor, J., Almassi, N., Upadhyay, S., Tyler, A. J., Berk, M. P., Hu, B., Hwang, T. H., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci98319 · Cited by 61
Xiao, L., Tien, J. C.-Y., Vo, J. N., Tan, M., Parolia, A., Zhang, Y., Wang, L., Qiao, Y., Shukla, S. K., Wang, X., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0941 · Cited by 58
“The clinical efficacies of therapies targeting AR, such as abiraterone and enzalutamide, have confirmed that AR signaling remains an important driver of CRPC (3,4,23).”
BackgroundZhang, Y., Dong, Y., Melkus, M. W., Yin, S., Tang, S.-N., Jiang, P., Pramanik, K., Wu, W., Kim, S., Ye, M., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1296 · Cited by 55
“In spite of significant advances in hormonal- (1, 2), and taxane-based chemotherapeutic (3, 4) modalities that have improved patient survival measured by months, there is currently no cure for castration-resistant prostate cancer (CRPC), following standard-of-care androgen deprivation therapy (ADT).”
BackgroundCurrent management of Cushing's disease
Tritos, N. A., & Biller, B. M. K. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12975 · Cited by 60
Molecular alterations and emerging targets in castration resistant prostate cancer
Lorente, D., & Bono, J. S. D. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2013.12.004 · Cited by 60
He, L., Fang, H., Chen, C., Wu, Y., Wang, Y., Ge, H., Wang, L., Wan, Y., & He, H. (2020) · Medicine · doi:10.1097/md.0000000000019760 · Cited by 58
Scher, H. I., Armstrong, A. J., Schonhoft, J. D., Gill, A. J., Zhao, J. L., Barnett, E. S., Carbone, E. A., Lu, J., Antonarakis, E. S., Luo, J., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.02.042 · Cited by 59
Self-citationChimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer
Perera, O. M., Thomas, P. B., Risbridger, G. P., Taylor, R. A., Azad, A., Hofman, M. S., Williams, E. D., & Vela, I. (2022) · Cancers · doi:10.3390/cancers14030503 · Cited by 55
“Abiraterone has also demonstrated similar results in chemotherapy-treated (COU-AA301) [15] and chemotherapy-naïve settings (COU-AA302) [16].”
ResultExpression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
Sperger, J. M., Helzer, K. T., Stahlfeld, C. N., Jiang, D., Singh, A., Kaufmann, K. R., Niles, D. J., Héninger, E., Rydzewski, N. R., Wang, L., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1305 · Cited by 58
Targeting the Apoptosis Pathway in Prostate Cancer
Zielinski, R., Eigl, B. J., & Chi, K. N. (2013) · The Cancer Journal · doi:10.1097/ppo.0b013e3182801cf7 · Cited by 63
Self-citationPayne, H. A., & Mason, M. D. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.385 · Cited by 55
Williams, S., Chiong, E., Lojanapiwat, B., Umbas, R., & Akaza, H. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70451-0 · Cited by 56
Regulation of tumor cell plasticity by the androgen receptor in prostate cancer
Bishop, J. L., Davies, A., Ketola, K., & Zoubeidi, A. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0137 · Cited by 57
Shiota, M., Yokomizo, A., Takeuchi, A., Imada, K., Kashiwagi, E., Song, Y., Inokuchi, J., Tatsugami, K., Uchiumi, T., & Naito, S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1809 · Cited by 54
“Food and Drug Administration (FDA) for use in a postchemotherapy setting in 2011 (3) and in a prechemotherapy setting in 2013 (4).”
BackgroundSternberg, C. N., Castellano, D., Daugaard, G., Géczi, L., Hotte, S. J., Mainwaring, P. N., Fred Saad, C., Souza, C. E., Tay, M. H., Garrido, J. M. T., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70417-6 · Cited by 57
Self-citationLokhandwala, P. M., Riel, S. L., Haley, L. M., Lu, C., Chen, Y., Silberstein, J. L., Zhu, Y., Zheng, G., Lin, M., Gocke, C. D., et al. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.08.003 · Cited by 56
Fankhauser, C. D., Schüffler, P. J., Gillessen, S., Omlin, A. G., Rupp, N. J., Rueschoff, J. H., Hermanns, T., Poyet, C., Sulser, T., Moch, H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22888 · Cited by 56
Diseases of the Abdomen and Pelvis 2018-2021
Hodler, J., Huch, R., & von Schulthess, G. K. (2018) · IDKD Springer series · doi:10.1007/978-3-319-75019-4 · Cited by 60
JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer
Paschalis, A., Welti, J. C., Neeb, A., Yuan, W., Figueiredo, I., Pereira, R., Ferreira, A., Riisnaes, R., Rodrigues, D. N., Jiménez‐Vacas, J. M., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-1807 · Cited by 54
Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy
Omlin, A. G., Pezaro, C., & Gillessen, S. (2013) · Therapeutic Advances in Urology · doi:10.1177/1756287213509677 · Cited by 58
McNeel, D. G., Eickhoff, J. C., Wargowski, E., Johnson, L. E., Kyriakopoulos, C. E., Emamekhoo, H., Lang, J. M., Brennan, M. J., & Liu, G. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004198 · Cited by 54
Han, D. G., Labaf, M., Zhao, Y., Owiredu, J. N., Zhang, S., Patel, K. J., Venkataramani, K., Steinfeld, J. S., Han, W., Li, M., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci168649 · Cited by 63
“Even with more aggressive AR signaling inhibition treatments (ARSi), such as enzalutamide or abiraterone, most patients eventually develop resistance (3, 4).”
Iuliani, M., Pantano, F., Buttigliero, C., Fioramonti, M., Bertaglia, V., Vincenzi, B., Zoccoli, A., Ribelli, G., Tucci, M., Vignani, F., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3724 · Cited by 55
Caffo, O., Pappagallo, G. L., Brugnara, S., Caldara, A., di Pasquale, M. C., Ferro, A., Frisinghelli, M., Murgia, V., Russo, L. M., Soini, B., et al. (2012) · Urology · doi:10.1016/j.urology.2011.11.043 · Cited by 57
Abiraterone and Novel Antiandrogens: Overcoming Castration Resistance in Prostate Cancer
Ferraldeschi, R., Pezaro, C. J., Karavasilis, V., & Bono, J. S. D. (2012) · Annual Review of Medicine · doi:10.1146/annurev-med-121211-091605 · Cited by 57
Ishibashi, Y., Tobisawa, Y., Hatakeyama, S., Ohashi, T., Tanaka, M., Narita, S., Koie, T., Habuchi, T., Nishimura, S., Οhyama, C., et al. (2014) · The Prostate · doi:10.1002/pros.22869 · Cited by 59
Pérez-López, R., Rodrigues, D. N., Figueiredo, I., Mateo, J., Collins, D. J., Koh, D., Bono, J. S. D., & Tunariu, N. (2017) · Investigative Radiology · doi:10.1097/rli.0000000000000415 · Cited by 58
Rendic, S. P., & Guengerich, F. P. (2018) · Drug Metabolism Reviews · doi:10.1080/03602532.2018.1483401 · Cited by 61
Clinical utility of emerging biomarkers in prostate cancer liquid biopsies
Boerrigter, E., Groen, L., van Erp, N. P., Verhaegh, G. W. C. T., & Schalken, J. A. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1675515 · Cited by 59
Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments
Tannock, I. F., Ratain, M. J., Goldstein, D. A., Lichter, A. S., Rosner, G. L., & Saltz, L. B. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02768 · Cited by 55
The 5α-androstanedione pathway to dihydrotestosterone in castration-resistant prostate cancer
Sharifi, N. (2012) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e31823874a4 · Cited by 52
Shore, N. D. (2015) · Urology · doi:10.1016/j.urology.2014.11.031 · Cited by 56
Patell, K., Kurian, M., Garcia, J. A., Mendiratta, P., Barata, P. C., Jia, A. Y., Spratt, D. E., & Brown, J. R. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2213892 · Cited by 62
“[11], enzalutamide (2012) [12], alpha-emitter radium-223 (2013) [13], rucaparib (2020) [14], and olaparib (2020) [15] for mCRPC [16].”
The utility of prostate‐specific antigen in the management of advanced prostate cancer
Crawford, E. D., Bennett, C. L., Andriole, G. L., Garnick, M. B., & Petrylak, D. P. (2013) · British Journal of Urology · doi:10.1111/bju.12061 · Cited by 54
Targeted α-Particle Therapy of Bone Metastases in Prostate Cancer
Jadvar, H., & Quinn, D. I. (2013) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000000290 · Cited by 57
Nishiyama, T. (2013) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2013.03.007 · Cited by 66
“[9] de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al.”
BackgroundLow Temperature Plasma: A Novel Focal Therapy for Localized Prostate Cancer?
Hirst, A. M., Frame, F. M., Maitland, N. J., & O’Connell, D. (2014) · BioMed Research International · doi:10.1155/2014/878319 · Cited by 56
“Even new generation androgen ablation drugs fail to deliver a life extension beyond several months [5].”
Omlin, A. G., Jones, R. J., van der Noll, R., Satoh, T., Niwakawa, M., Smith, S. A., Graham, J., Ong, M., Finkelman, R. D., Schellens, J. H. M., et al. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0235-5 · Cited by 56
Self-citationDorff, T. B., & Crawford, E. D. (2012) · Annals of Oncology · doi:10.1093/annonc/mds216 · Cited by 57
Blackledge, M., Tunariu, N., Orton, M. R., Padhani, A. R., Collins, D. J., Leach, M. O., & Koh, D. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153840 · Cited by 52
“The emergence of new, targeted therapy has brought optimism for the treatment of metastatic bone disease, which can prolong patient survival and prevent adverse skeletal events [20,21].”
BackgroundTargeting persistent androgen receptor signaling in castration-resistant prostate cancer
Graham, L. S., & Schweizer, M. T. (2016) · Medical Oncology · doi:10.1007/s12032-016-0759-3 · Cited by 56
Sabharwal, N., & Sharifi, N. (2019) · Endocrinology · doi:10.1210/en.2019-00366 · Cited by 55
Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes
Claps, M., Mennitto, A., Guadalupi, V., Sepe, P., Stellato, M., Zattarin, E., Gillessen, S., Sternberg, C. N., Berruti, A., de Braud, F., et al. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102057 · Cited by 54
Self-citationHeidenreich, A., Gillessen, S., Heinrich, D. A., Keizman, D., O’Sullivan, J. M., Carles, J., Wirth, M. P., Miller, K., Reeves, J. A., Seger, M. A., et al. (2019) · BMC Cancer · doi:10.1186/s12885-018-5203-y · Cited by 57
Swami, U., Sinnott, J. A., Haaland, B. A., Sayegh, N., McFarland, T. R., Tripathi, N., Maughan, B. L., Rathi, N., Sirohi, D., Nussenzveig, R. H., et al. (2021) · Cancers · doi:10.3390/cancers13194951 · Cited by 59
Martori, C., Sánchez-Moral, L., Paul, T., Pardo, J. C., Pous, A. F., de Porras, V. R., & Sarrias, M. (2022) · Cancers · doi:10.3390/cancers14020440 · Cited by 53
“However, over the last ten years the therapeutic landscape of mCRPC has changed dramatically [6] thanks to the discovery and subsequent approval of the second-generation taxane cabazitaxel [7], new androgen receptor signaling inhibitors (ARSIs) such as abiraterone [8,9] and enzalutamide [10], the alpha-emitter radium-…”
BackgroundDong, Q., Qiu, H., Piao, C., Li, Z., & Cui, X. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02774-2 · Cited by 60
“With the help of androgen-deprivation therapy (ADT), the overall survival for PCa patients in the first five years after initial diagnosis could reach 90% or even higher [4, 5].”
BackgroundMethodFOXA2 rewires AP-1 for transcriptional reprogramming and lineage plasticity in prostate cancer
Wang, Z., Townley, S. L., Zhang, S., Liu, M., Li, M., Labaf, M., Patalano, S. C., Venkataramani, K., Siegfried, K. R., Macoska, J. A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49234-9 · Cited by 59
“In our recent reports 26 , we discovered that LSD1 (Lysine-Speci fi c Demethylase 1 or KDM1A), a well-known lysine demethylase for mono-or di-methylated histone 3 lysine 4 (H3K4me1,2) 27,28 , acts as a binding partner of FOXA1 at enhancer regions 29 .”
InfluentialLHRH Agonists for the Treatment of Prostate Cancer: 2012.
Lepor, H., & Shore, N. D. (2012) · Europe PMC (PubMed Central) · Cited by 63
Sergio Bracarda, A., Gernone, A., Gasparro, D., Marchetti, P., Ronzoni, M., Bortolus, R., Fratino, L., Basso, U., Mazzanti, R., Messina, C., et al. (2013) · Future Oncology · doi:10.2217/fon.13.256 · Cited by 53
Hsp90: Still a viable target in prostate cancer
Centenera, M. M., Fitzpatrick, A. K., Tilley, W. D., & Butler, L. M. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.12.005 · Cited by 53
Current status of immunological therapies for prostate cancer
Antonarakis, E. S., & Drake, C. G. (2010) · Current Opinion in Urology · doi:10.1097/mou.0b013e3283381793 · Cited by 54
Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer
Persson, J. L., Semenas, & Dizeyi (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s45703 · Cited by 60
New and Emerging Therapies for Bone Metastases in Genitourinary Cancers
Saylor, P. J., Armstrong, A. J., Fizazi, K. S., Freedland, S. J., Saad, F., Smith, M. R., TOMBAL, B. F., & Pienta, K. J. (2012) · European Urology · doi:10.1016/j.eururo.2012.10.007 · Cited by 51
“New hormonal agents such as abiraterone acetate and enzalutamide (MDV3100) have demonstrated reductions in SREs [32,33], providing evidence that control of tumor growth can reduce the risk of bone complications.”
BackgroundSelf-citationAzad, A., Leibowitz‐Amit, R., Eigl, B. J., Lester, R. E., Wells, J. C., Murray, R. N., Kollmannsberger, C., Heng, D. Y. C., Joshua, A. M., & Chi, K. N. (2014) · The Prostate · doi:10.1002/pros.22872 · Cited by 49
“6 months compared to prednisone alone in mCRPC patients previously treated with docetaxel [7].”
BackgroundSelf-citationDivergent Androgen Receptor and Beta-Catenin Signaling in Prostate Cancer Cells
Lee, E., Ha, S., & Logan, S. K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141589 · Cited by 53
“Despite the promise of these and other therapeutics, they extend life by only 6–8 months [4, 5], indicating the need for a new approach to treat advanced disease.”
BackgroundMouse Models in Prostate Cancer Translational Research: From Xenograft to PDX
Rea, D., Vecchio, V. D., Palma, G., Barbieri, A., Falco, M., Luciano, A., Biase, D. D., Perdonà, S., Facchini, G., & Arra, C. (2016) · BioMed Research International · doi:10.1155/2016/9750795 · Cited by 58
Peng, H.-M., Im, S.-C., Pearl, N. M., Turcu, A. F., Rege, J., Waskell, L., & Auchus, R. J. (2016) · Biochemistry · doi:10.1021/acs.biochem.6b00532 · Cited by 50
Serritella, A. V., Shevrin, D., Heath, E. I., Wade, J. L., Martinez, E., Anderson, A. K. L., Schonhoft, J. D., Chu, Y.-L., Karrison, T., Stadler, W. M., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-4049 · Cited by 59
Wasmuth, E. V., Hoover, E. A., Antar, A., Klinge, S., Chen, Y., & Sawyers, C. L. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1922159117 · Cited by 50
Turco, F., Gillessen, S., Cathomas, R. L., Buttigliero, C., & Vogl, U. M. (2022) · Research and Reports in Urology · doi:10.2147/rru.s360444 · Cited by 58
“15,16 However, in daily clinical practice the majority of chemotherapy-fit patients who received abiraterone or enzalutamide as first-line treatment for mCRPC will receive docetaxel subsequently.”
The testosterone paradox of advanced prostate cancer: mechanistic insights and clinical implications
Kumar, R., Sena, L. A., Denmeade, S. R., & Kachhap, S. K. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00686-y · Cited by 62
Hussain, M., Kocherginsky, M., Agarwal, N., Adra, N., Zhang, J., Paller, C. J., Picus, J., Reichert, Z. R., Szmulewitz, R. Z., Tagawa, S. T., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1402 · Cited by 59
Targeting the androgen receptor signalling axis in castration‐resistant prostate cancer (CRPC)
Tsao, C., Galsky, M. D., Small, A., Yee, T., & Oh, W. K. (2012) · British Journal of Urology · doi:10.1111/j.1464-410x.2012.11445.x · Cited by 60
FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer
Jones, D. L., Wade, M., Nakjang, S., Chaytor, L., Grey, J., Robson, C. N., & Gaughan, L. (2015) · Oncotarget · doi:10.18632/oncotarget.4927 · Cited by 51
“The development of second generation anti-androgen therapies, such as Enzalutamide [4, 5] and abiraterone [6, 7], have shown promise in the treatment of CRPC, but are not effective in all patients and the development of resistance has limited their success in the clinic [8, 9].”
Progress of molecular targeted therapies for prostate cancers
Fu, W., Madan, E., Yee, M., & Zhang, H. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.11.003 · Cited by 55
Hoefeler, H., Duran, I., Hechmati, G., Garzon Rodriguez, C., Lüftner, D., Ashcroft, J., Bahl, A., Atchison, C., Wei, R., Thomas, E., et al. (2014) · Journal of Bone Oncology · doi:10.1016/j.jbo.2014.04.001 · Cited by 50
Chi, K. N., Gleave, M. E., Fazli, L., Goldenberg, S. L., So, A., Kollmannsberger, C., Murray, N., Tinker, A. V., & Pollak, M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0482 · Cited by 51
“ation hormone therapy such as abiraterone acetate (35) and MDV-3100 (36) should also be explored.”
BackgroundSelf-citationHeck, M. M., Thaler, M., Schmid, S. C., Seitz, A.-K., Tauber, R., Kübler, H. R., Maurer, T., Thalgott, M. K., Hatzichristodoulou, G., Höppner, M., et al. (2016) · British Journal of Urology · doi:10.1111/bju.13493 · Cited by 51
Heller, G., Fizazi, K. S., McCormack, R., Molina, A., MacLean, D. B., Webb, I. J., Fred Saad, C., Bono, J. S. D., & Scher, H. I. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1224 · Cited by 52
“5 The analysis was performed using data from patients enrolled in the phase III registration trial of abiraterone acetate plus prednisone (COU-AA-301; NCT00638690) (7, 8) and independently validated using the data from patients in a second registration trial of similar design evaluating orteronel plus prednisone (ELM-…”
InfluentialSelf-citationClonal Evolution and Epithelial Plasticity in the Emergence of AR-Independent Prostate Carcinoma
Laudato, S., Aparicio, A. M., & Giancotti, F. G. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.05.008 · Cited by 50
Metadata
- Authors
- de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., Staffurth, J. N., Mainwaring, P., Harland, S., Flaig, T. W., Hutson, T. E., Cheng, T., Patterson, H., Hainsworth, J. D., Ryan, C. J., Sternberg, C. N., Ellard, S. L., Fléchon, A., Saleh, M., Scholz, M., Efstathiou, E., Zivi, A., Bianchini, D., Loriot, Y., Chieffo, N., Kheoh, T., Haqq, C. M., & Scher, H. I.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Institut Gustave Roussy (FR)
- Cross Cancer Institute (CA)
- BC Cancer Agency (CA)
- University of Glasgow (GB)
- Institute of Cancer Research (GB)
- Velindre Cancer Centre (GB)
- University College London (GB)
- University of Colorado Cancer Center (US)
- University of Calgary (CA)
- University of California, San Francisco (US)
- Azienda Ospedaliera San Camillo-Forlanini (IT)
- Centre Léon Bérard (FR)
- Georgia Cancer Specialists (US)
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Logothetis, Christopher J.
- Molina, Arturo
- Fizazi, Karim
- North, Scott
- Chi, Kim N.
- Jones, Robert J.
- Goodman, Oscar B.
- Staffurth, John N.
- Mainwaring, Paul
- Flaig, Thomas W.
- Hutson, Thomas E.
- Cheng, Tina
- Hainsworth, John D.
- Ryan, Charles J.
- Sternberg, Cora N.
- Ellard, Susan L.
- Fléchon, Aude
- Saleh, Mansoor
- Efstathiou, Eleni
- Bianchini, Diletta
- Loriot, Yohann
- Kheoh, Thian
- Haqq, Christopher M.
- Scher, Howard I.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-05-26
- Volume
- 364
- Issue
- 21
- Pages
- 1995-2005
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3471149
- OpenAlex
- W2110534364
- Cited by
- 4,407
- References
- 54
- Citations by year
- 2026: 111 · 2025: 184 · 2024: 187 · 2023: 209 · 2022: 235 · 2021: 287 · 2020: 290 · 2019: 299 · 2018: 332 · 2017: 322 · 2016: 342 · 2015: 352 · 2014: 384 · 2013: 403 · 2012: 347
- FWCI
- 336.57
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Funders
- Prostate Cancer Foundation
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Exelixis
- Les Laboratories Pierre Fabre
- NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
- National Institute for Health and Care Research
- Astellas Pharma
- Genentech
- Foundation Medicine
- Medical Research Council
- National Cancer Institute (P50CA092629)
- Cilag
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- abiraterone, metastatic castration-resistant prostate cancer, androgen biosynthesis inhibition, overall survival, docetaxel, prednisone, prostate-specific antigen progression, progression-free survival, fluid retention, hypokalemia, hypertension
- MeSH terms
- Aged, Androgen Antagonists, Androgens, Androstenes, Androstenols, Antineoplastic Combined Chemotherapy Protocols, Double-Blind Method, Fatigue, Humans, Male, Middle Aged, Neoplasm Metastasis, Prednisone, Prostatic Neoplasms, Steroid 17-alpha-Hydroxylase, Survival Analysis, Treatment Outcome, Disease Progression, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.